Jori Symons1, Paul U Cameron1,2, Sharon R Lewin1,2. 1. The Peter Doherty nstitute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, Victoria. 2. Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia.
Abstract
PURPOSE OF REVIEW: To provide an overview of recent research of how HIV integration relates to productive and latent infection and implications for cure strategies. RECENT FINDINGS: How and where HIV integrates provides new insights into how HIV persists on antiretroviral therapy (ART). Clonal expansion of infected cells with the same integration site demonstrates that T-cell proliferation is an important factor in HIV persistence, however, the driver of proliferation remains unclear. Clones with identical integration sites harbouring defective provirus can accumulate in HIV-infected individuals on ART and defective proviruses can express RNA and produce protein. HIV integration sites differ in clonally expanded and nonexpanded cells and in latently and productively infected cells and this influences basal and inducible transcription. There is a growing number of cellular proteins that can alter the pattern of integration to favour latency. Understanding these pathways may identify new interventions to eliminate latently infected cells. SUMMARY: Using advances in analysing HIV integration sites, T-cell proliferation of latently infected cells is thought to play a major role in HIV persistence. Clonal expansion has been demonstrated with both defective and intact viruses. Production of viral RNA and protein from defective viruses may play a role in driving chronic immune activation. The site of integration may determine the likelihood of proliferation and the degree of basal and induced transcription. Finally, host factors and gene expression at the time of infection may determine the integration site. Together these new insights may lead to novel approaches to elimination of latently infected cells.
PURPOSE OF REVIEW: To provide an overview of recent research of how HIV integration relates to productive and latent infection and implications for cure strategies. RECENT FINDINGS: How and where HIV integrates provides new insights into how HIV persists on antiretroviral therapy (ART). Clonal expansion of infected cells with the same integration site demonstrates that T-cell proliferation is an important factor in HIV persistence, however, the driver of proliferation remains unclear. Clones with identical integration sites harbouring defective provirus can accumulate in HIV-infected individuals on ART and defective proviruses can express RNA and produce protein. HIV integration sites differ in clonally expanded and nonexpanded cells and in latently and productively infected cells and this influences basal and inducible transcription. There is a growing number of cellular proteins that can alter the pattern of integration to favour latency. Understanding these pathways may identify new interventions to eliminate latently infected cells. SUMMARY: Using advances in analysing HIV integration sites, T-cell proliferation of latently infected cells is thought to play a major role in HIV persistence. Clonal expansion has been demonstrated with both defective and intact viruses. Production of viral RNA and protein from defective viruses may play a role in driving chronic immune activation. The site of integration may determine the likelihood of proliferation and the degree of basal and induced transcription. Finally, host factors and gene expression at the time of infection may determine the integration site. Together these new insights may lead to novel approaches to elimination of latently infected cells.
Authors: Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano Journal: Nat Med Date: 2003-05-18 Impact factor: 53.440
Authors: T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci Journal: Proc Natl Acad Sci U S A Date: 1997-11-25 Impact factor: 11.205
Authors: Thomas A Rasmussen; Martin Tolstrup; Christel R Brinkmann; Rikke Olesen; Christian Erikstrup; Ajantha Solomon; Anni Winckelmann; Sarah Palmer; Charles Dinarello; Maria Buzon; Mathias Lichterfeld; Sharon R Lewin; Lars Østergaard; Ole S Søgaard Journal: Lancet HIV Date: 2014-09-15 Impact factor: 12.767
Authors: Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly Journal: Nat Med Date: 2009-06-21 Impact factor: 53.440
Authors: David McDonald; Marie A Vodicka; Ginger Lucero; Tatyana M Svitkina; Gary G Borisy; Michael Emerman; Thomas J Hope Journal: J Cell Biol Date: 2002-11-04 Impact factor: 10.539
Authors: Francesco Andrea Procopio; Rémi Fromentin; Deanna A Kulpa; Jessica H Brehm; Anne-Gaelle Bebin; Matthew C Strain; Douglas D Richman; Una O'Doherty; Sarah Palmer; Frederick M Hecht; Rebecca Hoh; Richard J O Barnard; Michael D Miller; Daria J Hazuda; Steven G Deeks; Rafick-Pierre Sékaly; Nicolas Chomont Journal: EBioMedicine Date: 2015-06-27 Impact factor: 8.143
Authors: Parmit Kumar Singh; Matthew R Plumb; Andrea L Ferris; James R Iben; Xiaolin Wu; Hind J Fadel; Brian T Luke; Caroline Esnault; Eric M Poeschla; Stephen H Hughes; Mamuka Kvaratskhelia; Henry L Levin Journal: Genes Dev Date: 2015-11-01 Impact factor: 11.361
Authors: Hannah S Sperber; Padma Priya Togarrati; Kyle A Raymond; Mohamed S Bouzidi; Renata Gilfanova; Alan G Gutierrez; Marcus O Muench; Satish K Pillai Journal: FASEB J Date: 2020-09-09 Impact factor: 5.191
Authors: Chantelle L Ahlenstiel; Geoff Symonds; Stephen J Kent; Anthony D Kelleher Journal: Front Cell Infect Microbiol Date: 2020-08-14 Impact factor: 5.293